Clinical Trial: People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07207148) titled 'People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists' on Sept. 17.

Brief Summary: The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not.

For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest.

For Aim 2, the clinical trial, PIRA will be measured pre-GLP-1 start and at study end (week 72). A composite score of disability, similar to the ORATORIO13 trial will be constructed including EDSS score, 25-foot timed walk, 9-hol...